N/A N=132 Anticoagulation Therapy in the Very Old
Atrial Fibrillation
Primary: Number of Patients Experiencing Stroke — 2; 2; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Changes From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) — -1.0; -1.5; -4.0; -5.5 units on a scale — p=<0.0001
Phase 4 N=19 Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers
Sleep Disorder, Shift-Work
Primary: Change in Average Total Sleep Time — 1.83; -0.33 hours/sleep opportunity — p=<0.05
Phase 1 N=114 A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®
Healthy
Primary: AUC0-inf，Area Under the Serum Concentration Versus Time Curve，Time 0 to Infinity — 30308695.01; 28449241.04; 29050169.73 hr*ng/mL
Phase 2 N=90 Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
Advanced Non-small Cell Lung Cancer (NSCLC)
Primary: Summary of Analysis of Progression-Free Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed…
N/A N=57 Effect of Varying Proportions of Low and High Energy Dense Foods Over 5 Days in Preschool Children
Feeding Behavior
Primary: Differences in Food and Beverage Intake by Energy — 1059; 1118; 977 kilocalories per day — p=<0.0001
Phase 3 N=1,842 A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in Hemoglobin A1c (HbA1c) From Baseline — -1.53; -1.71; -1.87 Percentage of HbA1c — p=0.003
N/A N=5,616 Evaluation of Peer Specialists on VA PACTs
Mental Illness · Physical Illness
Primary: Patient Activation Measure Change — 41.0; 41.6; 39.9; 40.6 Score on a scale — p=0.39
Phase 3 N=272 Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Prostatitis
Primary: Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks — 68; 66 Participants — p=0.99
N/A N=246 A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)
Crohn Disease · Colitis, Ulcerative · Inflammatory Bowel Disease
Primary: Crohn's Disease: Percentage of Participants With Active CD at Day 1 — 9.3 percentage of participants
N/A N=507 Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry
Influenza
Primary: Number of Subjects Reported With Exposure and Outcomes, Stratified by Trimester of Exposure, in Pregnant Women Intentionally or Unintentionally Vaccinated With FluLaval…
Phase 1 N=155 Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Malignant Melanoma
Primary: Investigator-Assessed Objective Response Rate (ORR) — 12.0; 36.4; 38.5 Percentage of Participants
Phase 2 N=25 REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
Thyroid Neoplasms
Primary: Response Rate — 17 Participants
N/A N=7 The Use of Psychomotor Vigilance Testing in the Assessment of Pediatric Obstructive Sleep Apnea
Pediatric Obstructive Sleep Apnea
Primary: Number of Participants Who Achieved Criteria of Obstructive Sleep Apnea in the PVT Assessment — 5; 2 Participants
Phase 3 N=533 Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
Duodenal Ulcer
Primary: Percentage of Participants With Endoscopically Confirmed Healing of Duodenal Ulcers — 96.9; 96.5 percentage of participants